Drive Therapeutics

Executive Summary

Drive Therapeutics is a preclinical-stage biotechnology company developing novel aptamer-based therapies for retinal diseases, including wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). Founded in 2019 and based in Cambridge, MA, the company leverages its proprietary aptamer platform to address key limitations of current anti-VEGF treatments, such as suboptimal efficacy and frequent injection intervals. By targeting multiple pathways involved in retinal pathology, Drive's candidates aim to improve visual outcomes and reduce treatment burden. The company is currently in Phase 1 clinical development, with initial data expected to validate its platform approach. As a private, early-stage firm, Drive faces typical challenges of securing financing and demonstrating proof-of-concept in humans. However, its differentiated strategy and focus on large, underserved ophthalmology markets position it as a potential player in the next generation of retinal therapies. The success of upcoming clinical milestones and partnerships will be critical to its advancement.

Upcoming Catalysts (preview)

• TBDPhase 1 interim safety and tolerability data readout25% success
• TBDSeries A or Series B financing round60% success
• TBDPartnership or licensing deal for aptamer platform30% success